Aelis Farma SA

DB:69O Stock Report

Market Cap: €43.6m

Aelis Farma Management

Management criteria checks 4/4

Aelis Farma's CEO is Pier Piazza, appointed in Jan 2022, has a tenure of 3.08 years. total yearly compensation is €473.61K, comprised of 63.3% salary and 36.7% bonuses, including company stock and options. directly owns 17.87% of the company’s shares, worth €7.79M. The average tenure of the management team and the board of directors is 3.1 years and 3.1 years respectively.

Key information

Pier Piazza

Chief executive officer

€473.6k

Total compensation

CEO salary percentage63.3%
CEO tenure3.1yrs
CEO ownership17.9%
Management average tenure3.1yrs
Board average tenure3.1yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Pier Piazza's remuneration changed compared to Aelis Farma's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024n/an/a

-€7m

Mar 31 2024n/an/a

-€6m

Dec 31 2023€474k€300k

-€5m

Sep 30 2023n/an/a

-€5m

Jun 30 2023n/an/a

-€6m

Mar 31 2023n/an/a

-€10m

Dec 31 2022€594k€296k

-€14m

Sep 30 2022n/an/a

-€14m

Jun 30 2022n/an/a

-€14m

Mar 31 2022n/an/a

-€6m

Dec 31 2021€501k€239k

€574k

Sep 30 2021n/an/a

€2m

Jun 30 2021n/an/a

€3m

Mar 31 2021n/an/a

€504k

Dec 31 2020€347k€210k

-€2m

Compensation vs Market: Pier's total compensation ($USD487.56K) is about average for companies of similar size in the German market ($USD456.62K).

Compensation vs Earnings: Pier's compensation has been consistent with company performance over the past year.

CEO

Pier Piazza (63 yo)

3.1yrs

Tenure

€473,614

Compensation

Dr. Pier Vincenzo Piazza, MD, Ph D., is CEO of Aelis Farma S.A. from January 11, 2022 and serves as its Director since 2017. Dr. Piazza is an entrepreneur and renowned scientist who has been involved in es...

Leadership Team

NamePositionTenureCompensationOwnership
Pier Piazza
CEO & Director3.1yrs€473.61k17.87%
€ 7.8m
Marie Lefevre
Head of Finance3.1yrsno datano data
Stephanie Monlezun
Chief Operating Officerno datano datano data
Lea Floquet
Head of Legal3.1yrsno datano data
Arsene Guekam
Chief Corporate Development Officer1.1yrsno datano data
Sandy Fabre
Head of Discovery & IP Leader3.1yrsno datano data
Aurelie Boucard
Head of Preclinical Development3.1yrsno datano data
Helle Mengel
Head of Clinical Development3.1yrsno datano data
Corinne Chaimbault
Head of Pharmaceutical Development3.1yrsno datano data

3.1yrs

Average Tenure

Experienced Management: 69O's management team is considered experienced (3.1 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Pier Piazza
CEO & Director8.1yrs€473.61k17.87%
€ 7.8m
Francois Thomas
Censor3.1yrs€30.00k11.78%
€ 5.1m
Anders Pedersen
Independent Chairman of the Board5yrs€100.00kno data
Robert Malenka
Chairman of the Scientific Advisory Boardno datano datano data
Daniele Piomelli
Member of Scientific Advisory Boardno datano datano data
Karen Linehan
Independent Director3.1yrsno datano data
Irina Staatz-Granzer
Independent Director3.1yrsno datano data
Markus Heilig
Member of Scientific Advisory Boardno datano datano data
Brahim Guetarni
Director4.1yrsno data8.63%
€ 3.8m
Karina Hansen
Independent Director3.1yrsno datano data
Keith Humphreys
Member of Scientific Advisory Boardno datano datano data

3.1yrs

Average Tenure

64yo

Average Age

Experienced Board: 69O's board of directors are considered experienced (3.1 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/03 00:25
End of Day Share Price 2025/02/03 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Aelis Farma SA is covered by 4 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Dylan van HaaftenBryan Garnier & Co
David SeynnaeveDegroof Petercam
Martial DescouturesODDO BHF Corporate & Markets